CASE REPORT

Successful Treatment With Third Stem Cell Transplant From an Allogeneic Donor for a Patient With Relapsed Diffuse Large B-Cell Lymphoma
Hirotaka Takasaki,1 Yoshimi Ishii,1 Wataru Yamamoto,1Hitoshi Tsuchihashi,1 Shigeki Motomura,1 Naoto Tomita,2 Yoshiaki Ishigatsubo,2 Rika Sakai1

High-dose chemotherapy with autologous stem cell transplant is commonly used for diffuse large B-cell lymphoma that recurs after successful salvage chemotherapy. However, in patients in whom the disease recurs again, the prognosis is poor. A 40-year-old woman who underwent allogeneic stem cell transplant 4 years after autologous stem cell transplant developed recurrent diffuse large B-cell lymphoma 3 years after the initial autologous stem cell transplant. She then underwent reduced-intensity hematopoietic stem cell transplant from a human leukocyte antigen-matched, unrelated donor who was not the previous autologous stem cell transplant donor. She achieved a long survival (328 days after the reduced-intensity hematopoietic stem cell transplant and 1844 days after the first allogeneic transplant). A second allogenic transplant may provide survival benefits in a proportion of patients with malignant lymphoma recurring after allogeneic transplant, although careful consideration is required because of the high risk of treatment-related mortality with second allogenic transplant.

Key words: Vasculopathy, Immunosuppression, Chronic rejection, Alloantibodies

Introduction

Standard therapy for diffuse large B-cell lymphoma (DLBCL) recurring after successful salvage chemotherapy is high-dose chemotherapy with autologous stem cell transplant (auto-SCT). However, if the disease recurs again after these therapies, the mean survival time of the patients is 7 to 8 months median survival duration.1,2 Standard therapy for such patients has not been established. Current treatments include chemotherapy with other drugs, a second trial of auto-SCT, and allogeneic stem cell transplant (allo-SCT). We report a patient who underwent allo-SCT 4 years after auto-SCT and developed recurrent DLBCL 3 years later. She then underwent reduced-intensity hematopoietic stem cell transplant (RIST) from an HLA-matched unrelated donor (HLA-MURD) who was not her previous allo-SCT donor, and she survived for a long time.

Case Report

A 40-year-old woman whose major complaint was pain in the left elbow visited a primary care doctor. A mass was found in the distal tip of the left humerus. Surgical removal of the lesion was performed in May 1993. Immunostaining revealed a diffuse proliferation of CD20-positive and CD79 a-positive medium and large lymphoma cells. Based on these findings, DLBCL was diagnosed. Chromosome analysis showed a normal karyotype, and the clinical stage was I EA. The first remission was achieved after 3 courses of CHOP therapy plus local radiation therapy at 40 Gy. However, recurrent lesions were found in the left humerus in January 1998 and in the nasal cavity in July 2000. The recurrences were treated by salvage chemotherapy. A third recurrence followed by salvage chemotherapy and auto-SCT was performed in June 2002. A high-dose regimen of ranimustine 300 mg/m2 on day 6, etoposide 200 mg/m2 from days 5 to 2, Ara-C 2 g/m2 from days 3 to 2, and melphalan 140 mg/ m2 on day 1 was administered.

In April 2006, she experienced a fourth relapse with bone metastases and bone marrow infiltration when she transferred to our hospital. At that time, multiple bone lesions and bone marrow infiltration were observed. Atypical cells in the bone marrow were CD19-, CD20-, and CD79 a-positive, and CD3- and CD10-negative medium and large cells. Therefore, recurrent DLBCL was diagnosed. At that time, performance status was 0, lactate dehydrogenase was 196 IU/L, the clinical re-stage was stage IV EA, and the secondary international prognostic index was low-intermediate risk. After 3 courses of combination therapy of rituximab and ESHAP (ie, rituximab 375 mg/m2 on day 1; etoposide 40 mg/m2 from days 2 to 5; carboplatin 37.5 mg/m2 from days 2 to 5; methylprednisolone 500 mg/body from days 2 to 6; and cytarabine 2000 mg/m2 on day 6), partial remission was achieved. In October 2006, RIST from HLA-A, HLA-B, HLA-DR antigens from a matched unrelated donor was performed after a conditioning regimen with cyclophosphamide 750 mg/m2 and fludarabine 25 mg/m2 from days −5 to −3. Grade 2 acute graft-versus-host disease developed 17 days after transplant, and this was relieved using only topical steroids. After that, extensive-type chronic acute graft-versus-host disease was observed; however, spontaneous remission occurred. Bone marrow examination did not show infiltration of lymphoma cells, and a positron emission tomography-computed tomography scan showed a reduced accumulation in bone lesions; complete remission after allo-SCT was diagnosed. However, in November 2009, enlargement of the left precordial region was observed and, based on a biopsy of the site, recurrence of DLBCL was diagnosed. Immunosuppressive drugs were discontinued 6 months after transplant. Donor lymphocyte infusion was considered, but consent for donor lymphocyte infusion was not obtained from the donor. Therefore, 4 courses of combination therapy of rituximab and EPOCH (rituximab 375 mg/m2 on day 1; etoposide 50 mg/m2 from days 2 to 5; vincristine 0.4 mg/m2 from days 2 to 5; Adriamycin 10 mg/m2 from days 2 to 5; cyclophosphamide 750 mg/m2 on day 6; and prednisolone 60 mg/m2 from days 2 to 6) were performed. We selected a different unrelated donor for the second allo-SCT because we were able to find a suitable HLA-MURD for the second allo-SCT, while none were available for the first allo-SCT. The second RIST HLA-A, HLA-B, HLA-DR antigens matching an unrelated another donor was performed in January 2011 (fludarabine 25 mg/m2 from days 8 to −4; melphalan 70 mg/m2 from days −3 to −2; and total body irradiation at 4 Gy on day −1). Hematopoietic stem cell transplant comorbidity index (HCT-CI) before RIST was 0. She has been in complete remission without severe complications (including acute graft-versus-host disease) to the time of this writing, and she has been surviving for 6 years since she relapsed after the initial allo-SCT.

Discussion

In the Parma study, in which patients with salvage chemotherapy-sensitive, recurrent aggressive non-Hodgkin lymphoma, were randomly assigned to undergo auto-SCT or to continue chemotherapy, overall survival was significantly longer in the auto-SCT group; now auto-SCT is considered standard therapy for chemotherapy-sensitive, recurrent aggressive non-Hodgkin lymphoma. However, the 5-year overall survival and disease-free survival after auto-SCT in Parma study were 53% and 46%; the outcome was not sufficiently favorable.3

It was reported that the poor prognostic factors after auto-SCT included unresponsiveness to salvage chemotherapy, high risk of relapse on secondary international prognostic index, and high risk of relapse on HCT-CI.4-6 Standard therapy for recurrence after auto-SCT has not been established. In a small number of patients who have undergone a second auto-SCT, the response rates to the second auto-SCT were 20% to 40% and treatment-related mortality occurred in 10% to 20% of patients. Various problems were highlighted, such as a potential increased risk of secondary cancer and difficulty obtaining enough stem cells.7,8 Compared to auto-SCT, the advantages of allo-SCT are that there is no possibility of tumor cell contamination and that graft-versus-lymphoma effect is expected.

Freytes and associates reported that the 5-year overall survival, disease-free survival, and treatment-related mortality after auto-SCT were 24%, 5%, and 25% in 114 patients with malignant lymphoma who received myeloablative conditioning regimen for recurrence after auto-SCT; and that poor prognostic factors included non-total body irradiation regimen and transplant in nonremission.9 On the other hand, it was reported that the 3-year overall survival, disease-free survival, and treatment-related mortality after RIST were 32%, 21%, and 44% in 263 patients with malignant lymphoma who underwent RIST for recurrence after auto-SCT, and that poor prognostic factors included non-total body irradiation regimen, transplant in nonremission, and poor performance status at transplant.10 In 101 patients with DLBCL who underwent allo-SCT (myeloablative conditioning regimen, n=37; RIST, n=64) for recurrence after auto-SCT, 3-year overall survival, progression-free survival, and treatment-related mortality were 54%, 42%, and 28% with no difference in outcome between pretransplant treatments. Poor prognostic factors included early relapse after auto-SCT, age 45 years or more, and transplant in nonremission.11 It is reported that RIST for malignant lymphoma recurring after auto-SCT may provide a similar outcome to myeloablative transplant; RIST did not always improve treatment-related mortality, so even when RIST is used, treatment-related mortality remains a problem.

This patient described here developed recurrent disease 4 years after auto-SCT and underwent RIST. Reduced-intensity hematopoietic stem cell transplant was selected, instead of a second auto-SCT, because the response to salvage therapy was only partial remission, HCT-CI before transplant was good, and cells from an HLA-MURD were available.

The patient again developed recurrent disease 3 years after the RIST. When recurrence occurs after allo-SCT, if severe acute graft-versus-host disease does not occur, immunosuppressive drugs are discontinued. Bishop and associates reported that the therapeutic effect of discontinuation of immunosuppressive drugs was observed in 60% of 15 patients with DLBCL recurring after allo-SCT; however, the long-term therapeutic effect is not known.12

Wudhikarn and associates conducted a study in 72 patients with malignant lymphoma that recurred after allo-SCT and reported that the 3-year survival rate was 44%. Discontinuation of immunosuppressive drugs was selected as a primary therapy in 81% of the patients; however, complete remission was achieved in only 13.8%; the remaining patients received chemotherapy, radiation therapy, donor lymphocyte infusion, or second allo-SCT as a secondary therapy. Wudhikarn and associates reported that poor prognostic factors included early (< 100 days) posttransplant relapse, a poor response to therapy after transplant, an advanced stage at relapse, and certain histologic types (Indolent [60%] vs Hodgkin [49%] vs DLBCL [46%] vs Mantle [43%] vs T/NK [39%] vs Burkitt [0%]; P = .05).13

There have been no reports on second allo-SCT for recurrence of malignant lymphoma after allo-SCT alone. In patients with hematopoietic malignancy who underwent second allo-SCT after first allo-SCT, 5-year overall survival, disease-free survival, and treatment-related mortality were 26% to 28%, 25% to 28%, and 30% to 46%; it was reported that poor prognostic factors included early posttransplant relapse, non-total body irradiation regimen, and age 20 years or more at second allo-SCT. It has been suggested that the therapeutic effect of retransplant may be expected in some hematopoietic malignancy patients whose time from the first allo-SCT to relapse was longer.14,15 In our patient, a favorable outcome was achieved, probably because recurrence occurred 4 years after the first allo-SCT and because HCT-CI at second allo-SCT remained good. There are no confirmatory data about an advantage for the selection of a different donor for the second SCT,16 although there are reports about this selection, including a study showing that different donor has a trend toward better outcome.15

In conclusion, we treated a patient with DLBCL recurring after autologous transplant and allo-SCT who underwent second allo-SCT and achieved a good therapeutic effect. Because the risk of treatment-related mortality in second allo-SCT is high, careful consideration is required when selecting patients for second allo-SCT. However, our experience suggests that second allo-SCT may provide a longer survival period in some patients with malignant lymphoma recurring after allo-SCT.

References:

  1. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32(7):673-679.
    CrossRef - PubMed
  2.  Kuittinen T, Wiklund T, Remes K, et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol. 2005;75(3):199-205.
    CrossRef - PubMed
  3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
    CrossRef - PubMed
  4. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989-1996.
    CrossRef - PubMed
  5.  Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92(10):3562-3568.
    PubMed
  6. Plattel WJ, Kluin-Nelemans HC, de Bock GH, van Imhoff GW. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2011;46(6):827-834.
    CrossRef - PubMed
  7. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol. 1997;15(4):1595-1600.
    PubMed
  8. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14(8):904-912.
    CrossRef - PubMed
  9. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104(12):3797-3803.
    CrossRef - PubMed
  10. Freytes CO, Zhang MJ, Carreras J, et al. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012;18(8):1255-1264.
    CrossRef - PubMed
  11. van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342-1348.
    CrossRef - PubMed
  12. Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008;19(11):1935-1940.
    CrossRef - PubMed
  13. Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant. 2011;17(10):1497-1504.
    CrossRef - PubMed
  14. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19(16):3675-3684.
    PubMed
  15. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721-727.
    CrossRef - PubMed
  16. Kato M, Horikoshi Y, Okamoto Y, et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant. 2012;47(10):1307-1311.
    CrossRef - PubMed
 

Volume : 11
Issue : 2
Pages : 199-202
DOI: 10.6002/ect.2012.0105

 

From the 1 Department of Medical Oncology, Kanagawa Cancer Center; and the 2 Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Corresponding author: Dr Hirotaka Takasaki, Department of Medical Oncology Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan
Phone:
+81 45 391 5761 Fax: +81 45 361 4692
E-mail: takasakih@kcch.jp

 

Copyright Baskent University 2003. Printed in Turkey. All Rights Reserved.